A Phase 2 interventional study of DDY391 and Placebo in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Arthritis, Rheumatoid by Novartis — 2 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.
Among the 31 studies in Arthritis, Rheumatoid by Novartis, this one is the 16th largest by planned enrollment, is the only one that started in 2027, is one of 10 in phase 2, and was the 31st registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 31 studies in Arthritis, Rheumatoid by Novartis are open now. Recruiting first, the newest first:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 7
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is close to the median of 95 across 2,225 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 96 across the 31 interventional studies. Of the 26 that completed or were terminated, 17 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Arthritis, Rheumatoid by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 2 study is:
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of DDY391 in adult participants with active moderate to severe rheumatoid arthritis. The study will enroll participants with an inadequate response (IR) and/or intolerance (INT) to 1-2 bDMARD, with different mechanisms of action (MoA), or with IR or INT to one prior JAKi.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive DDY391 Dose A.
Drug: DDY391
Participants will receive DDY391 Dose B.
Drug: DDY391
Participants will receive matching placebo.
Drug: Placebo
DDY391
Matching placebo
Number of participants achieving American College of Rheumatology 50 (ACR50) response
To evaluate the efficacy of DDY391 versus placebo through achievement of ACR 50.
Time frame: Week 12
Change from baseline in disease activity score 28 C-reactive protein (DAS28-CRP)
To evaluate the efficacy of DDY391 versus placebo through DAS28 CRP.
Time frame: Week 12
Incidence and severity of treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.
Time frame: through Week 16
No study locations are listed for this record.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for May 2028, 15 months later.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 15 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DDY391